Cyteir Therapeutics Management
Management criteria checks 3/4
Cyteir Therapeutics' CEO is Markus Renschler, appointed in Jan 2018, has a tenure of 6.17 years. total yearly compensation is $1.20M, comprised of 46.6% salary and 53.4% bonuses, including company stock and options. directly owns 3.07% of the company’s shares, worth $3.32M. The average tenure of the management team and the board of directors is 6.2 years and 6.2 years respectively.
Key information
Markus Renschler
Chief executive officer
US$1.2m
Total compensation
| CEO salary percentage | 46.6% |
| CEO tenure | 6.2yrs |
| CEO ownership | 3.1% |
| Management average tenure | 6.2yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
Is Cyteir Therapeutics (NASDAQ:CYT) In A Good Position To Deliver On Growth Plans?
Oct 25
Cyteir Therapeutics GAAP EPS of -$0.34
Aug 08Cyteir Therapeutics (NASDAQ:CYT) Is In A Good Position To Deliver On Growth Plans
Jul 21Here's Why We're Not Too Worried About Cyteir Therapeutics' (NASDAQ:CYT) Cash Burn Situation
Apr 21Companies Like Cyteir Therapeutics (NASDAQ:CYT) Are In A Position To Invest In Growth
Jan 06We're Not Very Worried About Cyteir Therapeutics' (NASDAQ:CYT) Cash Burn Rate
Sep 21Cyteir Therapeutics closes lower on first day of trading
Jun 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$33m |
| Jun 30 2023 | n/a | n/a | -US$41m |
| Mar 31 2023 | n/a | n/a | -US$44m |
| Dec 31 2022 | US$1m | US$559k | -US$46m |
| Sep 30 2022 | n/a | n/a | -US$49m |
| Jun 30 2022 | n/a | n/a | -US$50m |
| Mar 31 2022 | n/a | n/a | -US$49m |
| Dec 31 2021 | US$4m | US$504k | -US$42m |
| Sep 30 2021 | n/a | n/a | -US$36m |
| Jun 30 2021 | n/a | n/a | -US$29m |
| Mar 31 2021 | n/a | n/a | -US$22m |
| Dec 31 2020 | US$736k | US$450k | -US$21m |
Compensation vs Market: Markus's total compensation ($USD1.20M) is above average for companies of similar size in the US market ($USD662.89K).
Compensation vs Earnings: Markus's compensation has been consistent with company performance over the past year.
CEO
Markus Renschler (62 yo)
6.2yrs
Tenure
US$1,198,665
Compensation
Dr. Markus F. Renschler, MD, serves as President and Chief Executive Officer at Cyteir Therapeutics, Inc. since January 2018 and also serves as its Director since May 2016. Dr. Markus Renschler joined Cyte...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Investor & Independent Chairman of the Board | 6.2yrs | US$145.46k | 1.05% $ 1.1m | |
| President | 6.2yrs | US$1.20m | 3.07% $ 3.3m | |
| Co-Founder | 12.2yrs | no data | no data | |
| CFO & Treasurer | 3.3yrs | no data | 0.28% $ 308.2k |
6.2yrs
Average Tenure
61yo
Average Age
Experienced Management: CYTT's management team is seasoned and experienced (6.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Investor & Independent Chairman of the Board | 6.2yrs | US$145.46k | 1.05% $ 1.1m | |
| President | 7.8yrs | US$1.20m | 3.07% $ 3.3m | |
| Independent Director | 6.2yrs | US$114.46k | 6.83% $ 7.4m | |
| Independent Director | 2.1yrs | US$172.07k | 0.063% $ 68.7k | |
| Independent Director | 2.1yrs | US$164.21k | 0.034% $ 36.5k |
6.2yrs
Average Tenure
62yo
Average Age
Experienced Board: CYTT's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/19 07:36 |
| End of Day Share Price | 2024/03/19 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cyteir Therapeutics, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Anupam Rama | J.P. Morgan |
| Jeff Hung | Morgan Stanley |